TAMPA, Fla.--(BUSINESS WIRE)--
Neutra Corp. (OTCBB: NTRR.OB - News), an emerging nutraceuticals provider, is excited to announce that clinical trials are now underway on its debut weight-loss supplement, Pure Plus.
Volunteers will test the supplement by taking a single dose once a day. One group will test the regular Pure Plus formulation and the other group will be given the supplement with the addition of the sub-atomic Bio-energy infusion. Neither group will know which of the formulas they have received. The trials will take 30 days to complete and results will be compiled within 30 days after test conclude.
Once testing and analysis are complete, NTRR will begin plans for the retail launch of Pure Plus. The revolutionary supplement will be the first in a product line of superior, all-natural nutraceuticals that the company is working to offer consumers as quickly as possible.
Neutra Corp. is developing Pure Plus and other new products to compete in the fast-growing nutraceuticals industry alongside Herbalife Ltd. (NYSE: HLF), Vitamin Shoppe (NYSE: VSI - News), Nutraceutical International Corp. (NASDAQ: NUTR) and Schiff Nutrition International Inc. (NYSE: WNI).
For more information on NTRR’s nutraceuticals initiative, please visit http://www.neutracorp.com/investors.
Follow NTRR on Twitter at www.twitter.com/neutracorp.
About Neutra Corp.
Neutra Corp. (www.neutracorp.com) is a healthy lifestyle company that specializes in the development and marketing of nutritional supplements, nutrient boosters, herbal remedies and other natural wellness solutions. The company is currently working to produce a full range of products to address every component of a healthy lifestyle, including muscle building, weight loss and general wellness through a daily nutrition regimen. For investing information and performance data, please visit www.neutracorp.com/investors.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.
See the article here:
NTRR Begins Clinical Trials of Breakthrough Weight-Loss Formula
